P/E ratio for Carisma Therapeutics (CARM)
P/E ratio as of January 2026 (TTM): 0.1365
According to Carisma Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.136452. At the end of 2024 the company had a P/E ratio of -0.3021.
P/E ratio history for Carisma Therapeutics from 2023 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -0.3021 | -73.3% |
| 2023 | -1.13 | -85.48% |
| 2022 | -7.79 | -49.9% |
| 2021 | -15.6 | -59.44% |
| 2020 | -38.3 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.